A Real-World Experience With Resmetirom: Tolerability and Access
Background and Aims: Metabolic dysfunction–associated steatohepatitis (MASH) is a progressive liver disease often leading to cirrhosis. Resmetirom is the first Food and Drug Administration–approved treatment for MASH. The aim of this study was to evaluate the tolerability of resmetirom for the treat...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Gastro Hep Advances |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772572325000962 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!